Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Memorial Sloan Kettering Cancer Center · Cornell University · +39 more institutions
Abstract
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusion–positive cancers, including those with resistance mutations such as ROS1 G2032R. Download a PDF of the Research Summary. In this registrational phase 1–2 trial, we assessed the efficacy and safety of repotrectinib in patients with advanced solid tumors, including ROS1 fusion–positive NSCLC. The primary efficacy end point in the phase 2 trial was confirmed objective…
Citation impact
- FWCI
- 76.71
- Percentile
- 100%
- References
- 20
Authors
33- ADAlexander DrilonCorresponding
Memorial Sloan Kettering Cancer Center, Cornell University, Université Paris-Saclay, Université Grenoble Alpes
- DRD. Ross Camidge
Université Grenoble Alpes, Cornell University, University of Colorado Anschutz Medical Campus, Memorial Sloan Kettering Cancer Center, Université Paris-Saclay
- WMW. Marston Linehan
Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Université Grenoble Alpes, Cornell University, Harvard University, Université Paris-Saclay
- SKSang‐We Kim
Memorial Sloan Kettering Cancer Center, Asan Medical Center, Université Paris-Saclay, Cornell University, Chris O’Brien Lifehouse, Université Grenoble Alpes
- BSBenjamin Solomon
Cornell University, Memorial Sloan Kettering Cancer Center, Université Grenoble Alpes, U-M Rogel Cancer Center, Université Paris-Saclay, Peter MacCallum Cancer Centre
Topics & keywords
- ROS1
- Medicine
- Internal medicine
- Clinical endpoint
- Lung cancer
- Confidence interval
- Oncology
- Phases of clinical research
- Good health and well-being